Previous 10 | Next 10 |
2023-11-07 06:04:37 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal Pharmaceuticals raises its FY outlook Amneal to reorganize and simplify corporate structure Seeking Alpha’s Quant Rating on Amn...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
‒ Q3 2023 Net Revenue of $620 million; GAAP Net Income of $10 million; Diluted EPS of $0.06 ‒ ‒ Q3 2023 Adjusted Net Income (1) of $60 million; Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Affirmed Pr...
Amneal Pharmaceuticals Inc. Class A (AMRX) is expected to report $0.1 for Q3 2023
2023-11-06 11:32:09 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, before market open. The consensus EPS Estimate is $0.13 (-7.1% Y/Y) and the consensus Revenue Estimate is $604.53M (+10.8% Y/Y). Over the...
2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...
2023-10-23 16:23:28 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal to reorganize and simplify corporate structure Amneal gets approval for generic injectable on FDA's shortage list For further details ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023. The Company also raised its financial guidance for the year ending December 31, 2023,...
2023-10-17 16:34:51 ET Amneal Pharmaceuticals ( NYSE: AMRX ) said that it plans to reorganize and simplify its corporate structure, which includes eliminating its umbrella partnership-C-corporation structure. The biotech company said it intends to convert to a more traditional c...
- Biosimilar candidates referencing Prolia ® and XGEVA ® - Builds on first year success of Amneal’s initial three biosimilar launches - Expands existing biosimilar partnership with mAbxience Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Am...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...